Doctor Clay Siegall is a co-founder at Seattle Genetics, a pharmaceutical company that was first established in 1998. Siegall serves as the chief executive officer, president and chairs the board of directors at Seattle Genetics. The company has managed to come up with an array of cancer therapies based on antibodies. A case in point is ADCETRIS which was speedily approved in 2011 by United States food and drug administration.
Siegall has been resourceful in several capital raising activities held at Seattle Genetics. For instance, he helped the company to secure over $675 million through private and public financing strategies. Dr. Siegall worked at National Cancer Institute from 1988 to 1991 when he joined Bristol-Myers Squibb pharmaceutical Research Institute. Dr. Siegall served in this Institute until 1997.
Apparently, he is a member of board of directors at Alder BioPharmaceutical, a reputable privately owned biotechnology company. It is important to note that Dr. Siegall has authored several publications and holds over 15 successful patents. Dr. Siegall attended Maryland University where he received a B.S. in Zoology. He also attended in George Washington University where he earned a Ph.D. in Genetics.
In his recent publications, Dr. Siegall noted that Flacco is ready to start the game on the onset of the season. With the back injury, Flacco acknowledged that his decision wasn’t ideal but insisted he was ready for the game. Raven was thrilled start the season by battling against Cincinnati Bengals. Joe Ravens showed at the field appeared physically fits even with a back injury that kept him away for one month.
Hurricane Irma is also among Dr. Siegall recent publications. Irma is the most powerful hurricane recorded in the Atlantic Ocean. The hurricane achieved maximum speeds of 185 miles per hour across Florida posing threats to the inhabitants of the area. Irma is now projected to cause severe destruction of properties.
Dr. Clay Siegall is a key player in cancer management. He resolved to start drug licensing to broaden the scope of cancer research and treatment. The later development of Antibody Drug Conjugates is a clear demonstration of his efforts in cancer management.